| 3.37 0.48 (16.61%) | 03-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 4.21 | 1-year : | 4.96 |
| Resists | First : | 3.61 | Second : | 4.25 |
| Pivot price | 2.99 |
|||
| Supports | First : | 2.57 | Second : | 2.14 |
| MAs | MA(5) : | 3.06 |
MA(20) : | 2.99  |
| MA(100) : | 2.53 |
MA(250) : | 2.94 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 35.5 |
D(3) : | 31.7 |
| RSI | RSI(14): 57.8 |
|||
| 52-week | High : | 6.5 | Low : | 1.15 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATLN ] has closed Bollinger Bands are 39.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.99 - 3.02 | 3.02 - 3.03 |
| Low: | 2.74 - 2.77 | 2.77 - 2.78 |
| Close: | 2.86 - 2.9 | 2.9 - 2.92 |
As of June 18, 2024, Atlantic International Corp. was acquired by Lyneer Investments, LLC, in a reverse merger transaction. Atlantic International Corp. operates as a life sciences instrumentation and research services company. It focuses on development of scientific assets and novel intellectual property across multiple omics fields. The company's True Single Molecule Sequencing technology (tSMS) platform offers a single molecule solution for DNA and RNA sequencing through detection of nucleic acids to researchers for analyzing many billions of single molecules in a single experiment and generate accurate and reproducible data. It provides solutions for various applications, such as biomarker discovery and diagnostic assay developments, including laboratories associated with universities, scientific research centers, government institutions, and biotechnology and pharmaceutical companies. In addition, the company has research and development agreement with U.S. Department of Justice's Federal Bureau of Investigation to evaluate and determine the forensic capabilities of direct RNA sequencing using tSMS platform; and Weizmann Institute of Science for developed and applied innovative single-molecule technologies. The company was formerly known as SeqLL Inc. and changed its name to Atlantic International Corp. in June 2024. The company was founded in 2013 and is headquartered in Billerica, Massachusetts.
Sun, 01 Mar 2026
Atlantic International Corp. (NASDAQ:ATLN) Sees Large Decrease in Short Interest - MarketBeat
Tue, 24 Feb 2026
Atlantic International (ATLN) Appoints New CFO Amid Major Global Expansion - Insider Monkey
Tue, 17 Feb 2026
Atlantic International Appoints Gateway Group to Lead Investor Relations Program - The Manila Times
Wed, 28 Jan 2026
Atlantic International completes Circle8 acquisition, expanding globally - TipRanks
Wed, 28 Jan 2026
Atlantic International Signs Multiple Material Agreements - TradingView
Fri, 23 Jan 2026
Atlantic International Corp.'s (NASDAQ:ATLN) Shares Leap 223% Yet They're Still Not Telling The Full Story - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 71 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 89.2 (%) |
| Held by Institutions | 2.3 (%) |
| Shares Short | 155 (K) |
| Shares Short P.Month | 266 (K) |
| EPS | -2.24 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.41 |
| Profit Margin | -22.7 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | -16.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 2.2 % |
| Gross Profit (p.s.) | 0.68 |
| Sales Per Share | 6.26 |
| EBITDA (p.s.) | -0.4 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 3 (M) |
| Levered Free Cash Flow | 16 (M) |
| PE Ratio | -1.52 |
| PEG Ratio | 0 |
| Price to Book value | -8.43 |
| Price to Sales | 0.53 |
| Price to Cash Flow | 71.25 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|